Loading stock data…
$186.99-0.70 (-0.37%)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Revolution Medicines, Inc. in the Healthcare sector is trading at $186.99 with a market capitalization of $44.4B. Wall Street consensus targets $258.84 (24 analysts), implying a +38.4% move over the next 12 months. The stock is currently 17% below its 52-week high of $224.31, remaining 21.2% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$505.13M↓ | -$445.22M↓ | -$361.63M↓ | -$315.27M↓ | -$264.71M |
| Net Income | -$644.37M↓ | -$453.82M↓ | -$364.89M↓ | -$305.21M↓ | -$247.79M |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as m...